Search research articles
Contact Us
Filters
Showing results (261-270 of 356) with videos related to
Page
of 36
Sort By:
BMC Medicine
|
November 11, 2015
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
Sara De Biasi, Stefania Cerri, Elena Bianchini, et al.
JAMA
|
May 19, 2024
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
Ganesh Raghu, Luca Richeldi, Evans R Fernández Pérez, et al.
Frontiers in Medicine
|
June 27, 2022
Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
Rossella Di Bidino, Paola Rogliani, Alfredo Sebastiani, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 14, 2024
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial
Luca Richeldi, Courtney Schiffman, Jürgen Behr, et al.
Vaccines
|
April 23, 2025
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
Emanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 30, 2024
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
Enrico De Lorenzis, Francesco Del Galdo, Gerlando Natalello, et al.
The Lancet. Respiratory Medicine
|
March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
The European Respiratory Journal
|
March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial
Marlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
The Lancet. Respiratory Medicine
|
September 5, 2020
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
Peter M George, Paolo Spagnolo, Michael Kreuter, et al.
Page
of 36
Search research articles
Search
Showing results (261-270 of 356) with videos related to
Sort By:
Page
of 36
BMC Medicine
|
November 11, 2015
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
Sara De Biasi, Stefania Cerri, Elena Bianchini, et al.
JAMA
|
May 19, 2024
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
Ganesh Raghu, Luca Richeldi, Evans R Fernández Pérez, et al.
Frontiers in Medicine
|
June 27, 2022
Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region
Rossella Di Bidino, Paola Rogliani, Alfredo Sebastiani, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 14, 2024
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial
Luca Richeldi, Courtney Schiffman, Jürgen Behr, et al.
Vaccines
|
April 23, 2025
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
Emanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 30, 2024
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
Enrico De Lorenzis, Francesco Del Galdo, Gerlando Natalello, et al.
The Lancet. Respiratory Medicine
|
March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
The European Respiratory Journal
|
March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial
Marlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
The Lancet. Respiratory Medicine
|
September 5, 2020
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
Peter M George, Paolo Spagnolo, Michael Kreuter, et al.
Page
of 36